Melissa E. Murray, Ph.D. leads the Translational Neuropathology laboratory in the Department of Neuroscience at Mayo Clinic in Florida. Dr. Murray holds the academic rank of Associate Professor of Neuroscience and has received numerous awards, including Web of Science Highly Cited Researcher designation, for her research that focuses on investigating the heterogeneity of Alzheimer’s disease (AD) with an emphasis on young-onset AD. Dr. Murray currently leads several efforts to modernize neuropathology through the application of digital pathology and artificial intelligence to objectively identify and quantify neuropathologic lesions. Her research has uncovered three subtypes of Alzheimer’s disease based upon topographic distribution of neuropathologic lesions. This discovery provided keen observations important to syndromic diversity of amnestic and non-amnestic clinical presentations. Her work in this area has yielded significant contributions published in high-impact clinical and translational journals, including: The Lancet Neurology, Acta Neuropathologica, JAMA Neurology, and most recently Nature Communications. Her investigations have expanded to uncover potential mechanisms of corticolimbic vulnerability that combined innovative techniques using digital pathology, next generation sequencing, and machine learning. Her team identified a novel tau binding partner, SERPINA5, which may act as an instigator in Alzheimer’s disease and could have intriguing implications for potentially minimizing neurodegeneration associated with neurofibrillary tangle accumulation. She has published over 210 scientific papers, with the bulk of her government and foundation-funded studies centered on unraveling the complexity of clinicopathologic heterogeneity of AD and related dementias. Dr. Murray’s State of Florida funded initiatives seek to improve our understanding of ethnoracial differences and similarities in neuropathologic distribution and severity of AD and co-existing pathology. She co-leads two multi-site Neuropathology Cores, which include the Longitudinal Early Onset Alzheimer’s Disease Study (LEADS) and ApoE Pathobiology in Aging and Alzheimer’s disease (EPAAD). Dr. Murray’s currently leads or co-leads three National Institute on Aging R01 grants focused on AD subtypes, tau positron emission tomography, and young-onset AD using multi-disciplinary approaches.